← All trials
NCT02008656
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2013
- Primary completion
- Nov 1, 2017
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 222
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Cornell UniversityLead sponsor
- Cornell UniversityOverall official - principal investigator
- Oregon Health and Science UniversityCollaborator
- University of California, IrvineCollaborator
- University of California, San FranciscoCollaborator
- University of ChicagoCollaborator
- University of South FloridaCollaborator
- University of VermontCollaborator
- University of WashingtonCollaborator
- University of RochesterCollaborator
- University of VirginiaCollaborator
- University of MichiganCollaborator
- Georgetown UniversityCollaborator
- Colon and Rectal Surgery Inc.Collaborator
- St. Joseph Hospital of OrangeCollaborator
- University of ColoradoCollaborator
- Bergan Mercy Medical CenterCollaborator
- Washington University in St. LouisCollaborator
- John Muir Physician Network Clinical Research CenterCollaborator
- Methodist Cancer Center, Houston, TexasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.